09 June 2000
Ann Transplant 2000; 5(2): 61-67 :: ID: 497528
The efficacy of heart transplantation for end-stage cardiac disease is generally accepted. Patient survival rates after 1, 5 and 10 years are about 90%, 80% and 50%, respectively  but its long-term success is limited by chronic rejection. Chronic rejection results in graft coronary artery occlusive disease which in turns leads to ischemia and organ destruction. In human heart transplants it is characterised by a process of accelerated coronary artery disease, also called graft vascular disease (GVD). This type of rejection is represented by concentric intimal thickening of the entire length of the coronary vessels.
Keywords: graft vascular disease, Heart Transplantation, Cytokines
Most Viewed Current Articles
26 Jan 2022 : Review articleRecurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models
Ann Transplant 2022; 27:e934924
24 Aug 2021 : Review articleNormothermic Machine Perfusion (NMP) of the Liver – Current Status and Future Perspectives
Ann Transplant 2021; 26:e931664
29 Dec 2021 : Original articleEfficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...
Ann Transplant 2021; 26:e933588